Dianthus Therapeutics (DNTH)
Develops self-injected complement and dual-pathway therapies for severe autoimmune diseases.
$106.20
Pre-market−0.12 (−0.11%)
At close$106.32(−0.28%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$1.02
Revenue estimate
$400.8K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.81−$0.82−$0.88−$0.97−$1.43−$0.85−$0.90Pending
Estimate−$0.85−$0.86−$0.86−$0.86−$0.98−$1.17−$0.85−$1.02
Surprise+4.7%+4.7%−2.3%−12.8%−45.9%+27.4%−6.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.3M$1.2M$193.0K$396.0K$284.0K$463.0K$761.0KPending
Estimate$955.2K$806.9K$864.7K$398.1K$552.2K$403.6K$297.2K$400.8K
Surprise+38.8%+44.1%−77.7%−0.5%−48.6%+14.7%+156.1%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.02 | — | — |
| Aug 2026 | −$0.85 | −$0.90 | −6.3% |
| May 2026 | −$1.17 | −$0.85 | +27.4% |
| Mar 2026 | −$0.98 | −$1.43 | −45.9% |
| Nov 2025 | −$0.86 | −$0.97 | −12.8% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$1.02 | — | — | $400.8K | — | — | — |
| Aug 4, 2026 | −$0.85 | −$0.90 | −6.3% | $297.2K | $761.0K | +156.1% | +1.9% |
| May 5, 2026 | −$1.17 | −$0.85 | +27.4% | $403.6K | $463.0K | +14.7% | +0.2% |
| Mar 9, 2026 | −$0.98 | −$1.43 | −45.9% | $552.2K | $284.0K | −48.6% | +9.7% |
| Nov 5, 2025 | −$0.86 | −$0.97 | −12.8% | $398.1K | $396.0K | −0.5% | +8.0% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 3, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Sep 30, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 8, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 3, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 3, 2020 | |||||||
| Nov 13, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 19, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 9, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||